0001493152-22-025660.txt : 20220912
0001493152-22-025660.hdr.sgml : 20220912
20220912173009
ACCESSION NUMBER: 0001493152-22-025660
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220908
FILED AS OF DATE: 20220912
DATE AS OF CHANGE: 20220912
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dake Benjamin T
CENTRAL INDEX KEY: 0001869248
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 221239337
MAIL ADDRESS:
STREET 1: C/O AEROVATE THERAPEUTICS, INC.
STREET 2: 200 BERKELEY STREET, FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
ownership.xml
X0306
4
2022-09-08
0
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001869248
Dake Benjamin T
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM,
MA
02451
0
1
0
0
See Remarks
Common Stock
2022-09-08
4
M
0
3120
1.74
A
3120
D
Common Stock
2022-09-08
4
S
0
2491
18.1426
D
629
D
Common Stock
2022-09-08
4
S
0
629
18.4234
D
0
D
Common Stock
2022-09-09
4
M
0
258
1.74
A
258
D
Common Stock
2022-09-09
4
M
0
4462
2.14
A
4720
D
Common Stock
2022-09-09
4
S
0
4544
17.5045
D
176
D
Common Stock
2022-09-09
4
S
0
176
18.5359
D
0
D
Stock Option (Right to Buy)
1.74
2022-09-08
4
M
0
648
0
D
2030-09-03
Common Stock
648
14746
D
Stock Option (Right to Buy)
1.74
2022-09-08
4
M
0
2472
0
D
2030-09-03
Common Stock
2472
34656
D
Stock Option (Right to Buy)
1.74
2022-09-09
4
M
0
258
0
D
2030-09-03
Common Stock
258
14488
D
Stock Option (Right to Buy)
2.14
2022-09-09
4
M
0
4462
0
D
2031-04-02
Common Stock
4462
44420
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.39 to $18.385, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.40 to $18.505, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.06 to $18.06, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.07 to $18.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with shares vesting in 48 substantially equal monthly installments.
Officer Title: President, Chief Operating Officer and Secretary
/s/ George A. Eldridge, Attorney-in-Fact
2022-09-12